Evidence map›Paper›PMID 37668111›Full record

ArticleNeuropsychopharmacology reports2023

DNA methylation status of SHATI/NAT8L promoter in the blood of cigarette smokers.

Naotaka Izuo, Hajime Miyanishi, Daisuke Nishizawa, Takuma Fujii, Junko Hasegawa, Naomi Sato, Fumihiko Tanioka, Haruhiko Sugimura, Kazutaka Ikeda, Atsumi Nitta

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuropsychopharmacology reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Naotaka IzuoDepartment of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Hajime MiyanishiDepartment of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Daisuke NishizawaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Takuma FujiiDepartment of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.
Junko HasegawaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Naomi SatoDepartment of Clinical Nursing, Hamamatsu University School of Medicine, Shizuoka, Japan.
Fumihiko TaniokaDepartment of Pathology, Iwata City Hospital, Shizuoka, Japan.
Haruhiko SugimuraDepartment of Tumor Pathology, Hamamatsu University School of Medicine, Shizuoka, Japan.
Kazutaka IkedaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.ORCID 0000-0001-8342-0278
Atsumi NittaDepartment of Pharmaceutical Therapy and Neuropharmacology, Faculty of Pharmaceutical Sciences, University of Toyama, Toyama, Japan.ORCID 0000-0001-6916-9160
University of Toyama · JPTokyo Metropolitan Institute of Medical Science · JPShizuoka University · JPIwata City Hospital · JP

Funding

Advenced Animal Model Support (AdAMS) from Japan Society for the Promotion of Science JP22H04922Japan Society for the Promotion of Science 17H04324Japan Society for the Promotion of Science 22J11998Japan Society for the Promotion of Science 22KJ1457Japan Society for the Promotion of Science 26293347Japan Society for the Promotion of Science JP17K08970Japan Society for the Promotion of Science JP20K09259Japan Society for the Promotion of Science JP21H02632Japan Society for the Promotion of Science JP21H03028Kobayashi FoundationOTC-Self-Medication Promotion FoundationSmoking Research Foundation
6 · The paper itself

Abstract

aimsCigarette smoking is a preventable risk factor for various diseases such as cancer, ischemic stroke, cardiac stroke, and chronic obstructive pulmonary disease. Smoking cessation is of great importance not only for individual smokers but also for social health. Regarding current cessation therapies, the effectiveness of nicotine replacement is limited, and the cost of varenicline medication is considerable. Thus, a method for screening smokers who are responsive to cessation therapy based on the therapeutic effectiveness is required. Peripheral biomarkers reflecting smoking dependence status are necessary to establish a method for achieving effective cessation therapy.

methodsMethylation status of smokers' blood DNA was evaluated focusing on SHATI/NAT8L, an addiction-related gene. Eight CpG sites in SHATI/NAT8L were quantified by pyrosequencing.

resultsThere was no difference in the methylation status of this gene between smokers (n = 129) and non-smokers (n = 129) at all CpG sites. No correlations between the methylation status of SHATI/NAT8L and indicators of smoking dependence were found.

conclusionsAlthough the present study found no significance in the DNA methylation of SHATI/NAT8L among smokers, the exploration of predictable peripheral biomarkers for the effectiveness of smoking cessation therapy is required.

Indexed as

Smoking CessationTobacco ProductsAcetyltransferasesBiomarkersDNA MethylationHumansSmokersTobacco Use Cessation DevicesAcetyltransferasesBiomarkersNAT8L protein, humancigarette smokerDNA methylationpyrosequencingSHATI/NAT8Ltobacco dependence screener

Identifiers

PMID37668111
PMCPMC10739067
OpenAlexW4386438416

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.